Journal: Neuropharmacology

Article Title: GSK3β inhibition protects the immature brain from hypoxic-ischemic insult via reduced STAT3 signalling

doi: 10.1016/j.neuropharm.2015.09.017

Figure Lengend Snippet: Localization of phosphorylated STAT3 (pSTAT3, activated form) by immunohistochemistry in (A) left injured ipsilateral hippocampus and (B) right non-injured hippocampus. Co-localization of pSTAT3 with blood vessel marker CD31 (C), astroglia marker GFAP (D), microglia marker Iba1/AIF1 (E) and neuronal marker NeuN (F). Scale bar is 300µm in A & B and 50µm in C-F.

Article Snippet: Double immune reactivity was performed on sections using antibodies against p-STAT3 (as above) mixed with one of the following antibodies and incubated overnight: mouse anti-glial fibrillary acidic protein (GFAP, 1:50; Sigma-Aldrich, clone G-A-5), goat anti-CD31 (1:100; RD Systems, AF3628), mouse anti-NeuN (1:50; Merck-Millipore, clone A60) or mouse anti-Iba1/AIF1 (1:750; Merck-Millipore, MABN92).

Techniques: Immunohistochemistry, Marker

Journal: Neuropharmacology

Article Title: GSK3β inhibition protects the immature brain from hypoxic-ischemic insult via reduced STAT3 signalling

doi: 10.1016/j.neuropharm.2015.09.017

Figure Lengend Snippet: Localization of phosphorylated STAT3 (pSTAT3, activated form) by immunohistochemistry in (A) left injured ipsilateral hippocampus and (B) right non-injured hippocampus. Co-localization of pSTAT3 with blood vessel marker CD31 (C), astroglia marker GFAP (D), microglia marker Iba1/AIF1 (E) and neuronal marker NeuN (F). Scale bar is 300µm in A & B and 50µm in C-F.

Article Snippet: Double immune reactivity was performed on sections using antibodies against p-STAT3 (as above) mixed with one of the following antibodies and incubated overnight: mouse anti-glial fibrillary acidic protein (GFAP, 1:50; Sigma-Aldrich, clone G-A-5), goat anti-CD31 (1:100; RD Systems, AF3628), mouse anti-NeuN (1:50; Merck-Millipore, clone A60) or mouse anti-Iba1/AIF1 (1:750; Merck-Millipore, MABN92).

Techniques: Immunohistochemistry, Marker

Journal: American Journal of Cancer Research

Article Title: Enhanced proton treatment with a LDLR-ligand peptide-conjugated gold nanoparticles targeting the tumor microenvironment in an infiltrative brain tumor model

doi:

Figure Lengend Snippet: Immunofluorescence data (staining with CD31, SMA, Ki67, and VEGF) showing enhanced reduction of both tumor mass and neoplastic TME with angiogenic invasion such as endothelial cell proliferation and pericytes invasion by combined proton treatment with TME-targeted gold NP. (A) Immunofluorescence staining of CD31 (green) and αSMA (red) cells from control mice, proton treated or proton + ApoB@AuNP treated mice. (A, upper: tumor mass, A, lower: neoplastic TME with angiogenic invasion), Scale bar =50 µm. Quantification of an average of five fields with high appear CD31+ αSMA+ cells per field (magnification, 200×, n>5). For graphs, error bars indicate ± SD. *P<0.05, **P<0.01, ***P<0.001. (B) Immunofluorescence staining of VEGF (green) and Ki67 (red) cells from control mice, proton treated or proton + ApoB@AuNP treated mice. (A, upper: tumor mass, A, lower: neoplastic TME with angiogenic invasion), Scale bar =50 µm. Quantification of an average of five fields with high appear VEGF+ Ki67+ cells per field (magnification, 200×, n>5). For graphs, error bars indicate ± SD. *P<0.05, **P<0.01, ***P<0.001.

Article Snippet: Next, the primary antibody was reacted, and the primary antibodies used were CD31 (Endothelial cell marker; 1:200; R&D Systems; #AF3628), αSMA (Fibroblast marker; 1:1000; Sigma-Aldrich; #A5228), Ki67 (Proliferation marker; 1:200; Acris, #DRM004) and VEGF (1:100; Santa-cruz, #SC-57496).

Techniques: Immunofluorescence, Staining, Control